Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Deal Watch Business Strategies M & A

Deal Watch: Visus Begins Charting Its Direction In Ophthalmology With Two Deals

  • News

Executive Summary

Seattle biotech raised $36m series A in March, now obtains glaucoma and AMD drug candidates along with delivery technology. Alligator, Orion partner on bispecific antibodies for cancer.

You may also be interested in...



Orasis Prepares To Battle AbbVie In Presbyopia

The privately held firm got FDA approval for Qlosi, which like AbbVie’s Vuity is a low-dose formulation of pilocarpine for age-related near vision loss. Launch is planned for early 2024.

Deal Watch: Bristol Accesses Tech Platforms From SyntheX, Autolus

Pharma will partner with SyntheX on targeted protein degradation, with Autolus on cell therapy safety. Novo Nordisk gets rights to Ventus’s lead compound in NASH and chronic kidney disease.

Biocon Biologics And Serum Institute Join Forces

Serum to hold 15% in Biocon arm Biocon Biologics as part of a broad alliance that expects to leverage the partners' strengths and resources in vaccines and biologics. Pursuing opportunities based on the hot mRNA technology platform appears firmly on the table.

Table

View full table

Related Content

Scrip
Scrip
Scrip
Scrip
Scrip
Scrip
Scrip

Topics

Related Companies

Tags:
Deal Watch Business Strategies M & A
Latest Headlines

China Seniors' Rising HIV Rates Pose Control Challenges

Seismic Rumbles Into Clinic With $121m For Novel Immunology Biologics

EyePoint Hits New Durability Milestone For Wet AMD Treatment

Roche Looks To Muscle Into Obesity Market With $2.7bn Carmot Buyout

See All
UsernamePublicRestriction

Register

SC144937

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By